Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
NCT ID: NCT06122610
Last Updated: 2026-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
10 participants
INTERVENTIONAL
2025-03-07
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will:
* Complete two phases involving 6 visits
* Undergo additional research PET/CT, and possibly SPECT/CT scans
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
NCT02359500
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
NCT03673943
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
NCT01967537
Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT
NCT04622631
Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities
NCT04152928
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this research, participants will be asked to complete a screening phase and possibly a dosimetry phase. The screening phase will require 2 visits. The dosimetry phase will also require 3 research visits.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants treated with Lutathera
Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
SPECT/CT will be performed after first cycle of Lutathera® treatment
Photon Emission Tomography / CT (PET/CT)
PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
64Cu-Dotatate
Standard of care administration of radioactive drug for PET/CT
177Lu-Dotatate
Standard of care administration of radioactive drug for PET/CT and SPECT/CT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
SPECT/CT will be performed after first cycle of Lutathera® treatment
Photon Emission Tomography / CT (PET/CT)
PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
64Cu-Dotatate
Standard of care administration of radioactive drug for PET/CT
177Lu-Dotatate
Standard of care administration of radioactive drug for PET/CT and SPECT/CT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Known incompatibility to CT. SPECT, or PET scans
* Unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Wisconsin, Madison
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Changhee Lee, MD
Role: PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Wisconsin - Madison
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Protocol Version 12/12/2025
Identifier Type: OTHER
Identifier Source: secondary_id
SMPH/RADIOLOGY/RADIOLOGY
Identifier Type: OTHER
Identifier Source: secondary_id
2023-0121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.